NO20082733L - Indol-3-yl-karbonyl-spiro-piperidinderivater - Google Patents

Indol-3-yl-karbonyl-spiro-piperidinderivater

Info

Publication number
NO20082733L
NO20082733L NO20082733A NO20082733A NO20082733L NO 20082733 L NO20082733 L NO 20082733L NO 20082733 A NO20082733 A NO 20082733A NO 20082733 A NO20082733 A NO 20082733A NO 20082733 L NO20082733 L NO 20082733L
Authority
NO
Norway
Prior art keywords
indol
carbonyl
spiropiperidine
spiro
relates
Prior art date
Application number
NO20082733A
Other languages
English (en)
Norwegian (no)
Inventor
Patrick Schnider
Hasane Ratni
Caterina Bissantz
Christophe Grundschober
Mark Rogers-Evans
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20082733L publication Critical patent/NO20082733L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20082733A 2006-01-05 2008-06-18 Indol-3-yl-karbonyl-spiro-piperidinderivater NO20082733L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06100118 2006-01-05
PCT/EP2006/069897 WO2007077122A1 (en) 2006-01-05 2006-12-19 Indol-3-yl-carbonyl-spiro-piperidine derivatives

Publications (1)

Publication Number Publication Date
NO20082733L true NO20082733L (no) 2008-10-02

Family

ID=37989141

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082733A NO20082733L (no) 2006-01-05 2008-06-18 Indol-3-yl-karbonyl-spiro-piperidinderivater

Country Status (15)

Country Link
US (1) US7351706B2 (ru)
EP (1) EP1973913A1 (ru)
JP (1) JP2009522318A (ru)
KR (1) KR101121349B1 (ru)
CN (1) CN101356174B (ru)
AR (1) AR059136A1 (ru)
AU (1) AU2006334423B2 (ru)
BR (1) BRPI0620951A2 (ru)
CA (1) CA2634120A1 (ru)
IL (1) IL192401A0 (ru)
NO (1) NO20082733L (ru)
RU (1) RU2420529C2 (ru)
TW (1) TW200734343A (ru)
WO (1) WO2007077122A1 (ru)
ZA (1) ZA200805574B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6374762B1 (en) * 1997-10-27 2002-04-23 Correct Craft, Inc. Water sport towing apparatus
MX2007002033A (es) 2004-08-19 2007-04-26 Vertex Pharma Moduladores de receptores muscarinicos.
US7786141B2 (en) * 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
RU2007124373A (ru) * 2004-11-29 2009-01-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы мускариновых рецептеров
WO2007039438A1 (en) * 2005-09-28 2007-04-12 F. Hoffmann-La Roche Ag Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists
JP2009521483A (ja) * 2005-12-22 2009-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
RU2008137593A (ru) * 2006-02-22 2010-03-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы мускариновых рецепторов
EP2051712A2 (en) * 2006-08-15 2009-04-29 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors
JP2010501561A (ja) * 2006-08-18 2010-01-21 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体の調節剤
DE602007006989D1 (en) * 2006-12-07 2010-07-15 Hoffmann La Roche Spiropiperidinderivate
EP2207549A1 (en) * 2007-10-03 2010-07-21 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors
US8846684B2 (en) 2011-03-31 2014-09-30 The Regents Of The University Of Michigan Arbovirus inhibitors and uses thereof
CA2866218C (en) 2012-03-16 2020-06-09 Vitae Pharmaceuticals, Inc. Liver x receptor modulators
DK2825542T3 (en) 2012-03-16 2017-01-09 Vitae Pharmaceuticals Inc LIVER-X-receptor modulators
BR112016013058B1 (pt) 2013-12-19 2021-02-23 F. Hoffmann-La Roche Ag Espiro-oxazolonas, seus usos, seus intermediários e composiçãofarmacêutica
ES2951874T3 (es) * 2017-09-05 2023-10-25 Neumora Therapeutics Inc Antagonistas del receptor de vasopresina y productos y métodos relacionados con los mismos
WO2020048828A1 (en) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048831A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048829A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 3,9-diazaspiro[5.5]undecane compounds
WO2020048830A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4349549A (en) * 1981-05-18 1982-09-14 Syntex (U.S.A.) Inc. Anti-hypertensive 1-substituted spiro(piperidine-oxobenzoxazine)s
CA2298813A1 (en) 1997-08-28 1999-03-04 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
US6013652A (en) 1997-12-04 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
WO2001022919A2 (en) 1999-09-30 2001-04-05 Merck & Co., Inc. Spiro[bicyclic -azacycloalkyl and -cycloalkyl] derivatives and uses thereof
GB0003397D0 (en) 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
SI1549638T1 (sl) 2002-10-03 2008-02-29 Hoffmann La Roche Indol-3-karboksiamidi kot aktivatorji glukokinaze(gk)
RU2414466C2 (ru) 2005-07-14 2011-03-20 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ ИНДОЛ-3-КАРБОНИЛ-СПИРО-ПИПЕРИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРОВ V1a

Also Published As

Publication number Publication date
RU2008125813A (ru) 2010-02-10
EP1973913A1 (en) 2008-10-01
US20070155761A1 (en) 2007-07-05
TW200734343A (en) 2007-09-16
KR20080073364A (ko) 2008-08-08
IL192401A0 (en) 2008-12-29
US7351706B2 (en) 2008-04-01
CN101356174A (zh) 2009-01-28
AU2006334423A1 (en) 2007-07-12
WO2007077122A1 (en) 2007-07-12
CN101356174B (zh) 2011-11-23
RU2420529C2 (ru) 2011-06-10
AR059136A1 (es) 2008-03-12
BRPI0620951A2 (pt) 2011-11-29
JP2009522318A (ja) 2009-06-11
ZA200805574B (en) 2009-12-30
CA2634120A1 (en) 2007-07-12
AU2006334423B2 (en) 2011-09-22
KR101121349B1 (ko) 2012-03-09

Similar Documents

Publication Publication Date Title
NO20082733L (no) Indol-3-yl-karbonyl-spiro-piperidinderivater
NO20080059L (no) Indol-3-karbonyl-spiro-piperidinderivater som V1A-reseptorantagonister
NO20080316L (no) Indol-3-yl-karbonylpiperidin- og piperazinderivater
NO20080291L (no) Indol-3-yl-karbonyl-piperidin-benzomidazolderivater som Via reseptorantagonister
NO20071660L (no) Nye pyridinonderivater og deres anvendelse som positive allosteriske modulatorer av MGLUR2-reseptorer
NO20083500L (no) 1,4-disubstituerte 3-cyano-pyridonderivater og deres anvendelse som positiv-allosteriske modulatorer av mGluR2 receptorer
WO2006021213A3 (en) Vasopressin v1a antagonists
NO20064579L (no) Bifenylforbindelser anvendelige som muskariniske receptorantagonister
NO20083909L (no) Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere
WO2007020213A3 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
NO20092762L (no) 2-aza-bicyklo[3.1.0]heksanderivater
NO20076060L (no) Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister
WO2010036613A8 (en) Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CY1108880T1 (el) Παραγωγα καρβοξαμιδιου ως ανταγωνιστες μουσκαρινικου υποδοχεα
JPWO2006051826A1 (ja) 含窒素複素環化合物およびその医薬用途
NO20063597L (no) Acetylinske piperazinforbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
WO2008099072A3 (fr) Nouveaux derives de 2, 4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
TW200640863A (en) Compounds which potentiate glutamate receptor and uses thereof in medicine
NO20091831L (no) Indoler
WO2008145524A3 (en) 4,4-disubstituted piperidine derivatives
MY139016A (en) PYRAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF ß-ADRENERGIC RECEPTOR KINASE 1
NO20091832L (no) Indoler som virker via reseptorantagonister
NO20063562L (no) Fusjonerte heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
WO2009034432A3 (en) Novel compounds active as muscarinic receptor antagonists
NO20092264L (no) Spiro-piperidinderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application